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Abstract
Background: CD44s is a cell adhesion molecule known to mediate cellular adhesion to the extracellular matrix, a
prerequisite for tumor cell migration. CD44s plays an important role in invasion and metastasis of various cancers.
In the present study, we sought to determine whether CD44s is involved in clinical outcomes of patients with
resected non-small cell lung cancer (NSCLC).
Methods: Using immunohistochemical staining, we investigated CD44s protein expression using tissue array
specimens from 159 patients with resected NSCLC (adenocarcinoma (AC; n = 82) and squamous cell carcinoma
(SCC; n = 77). Additionally, the immunoreactivity of cyclooxygenase (COX)-2 was also studied. The
clinicopathological implications of these molecules were analyzed statistically.
Results: High CD44s expression was detected more frequently in NSCLC patients with SCC (66/72; 91.7%) than in
those with AC histology (P< 0.001). Additionally, high CD44s expression was significant correlated with more
advanced regional lymph node metastasis (P = 0.021). In multivariate analysis of survival in NSCLC patients with AC
histology, significant predictors were lymph node metastasis status (P < 0.001), high-grade tumor differentiation (P
= 0.046), and high CD44s expression (P=0.014). For NSCLC patients with SCC histology, the significant predictor
was a more advanced tumor stage (P=0.015). No significant association was found between CD44s and clinical
outcome (P = 0.311).
Conclusions: High CD44s expression was a negative prognostic marker with significance in patients with resected
NSCLC, particularly those with AC histology, and was independent of tumor stage.
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Background
Cell adhesion molecules control cell behavior through
interactions with each other and with their microenvir-
onment by exchanging information through cell-cell and
cell-extracellular matrix (ECM) interactions [1]. As a
cell adhesion molecule, CD44, a widely expressed cell-
surface glycoprotein and a cell-surface receptor for hya-
luronate and osteopontin, is known to mediate cellular
adhesion to the ECM, which is a prerequisite for tumor
cell migration [2]. CD44 is the product of a single gene
located on the short arm of human chromosome 11; the
entire human CD44 gene is encoded by 60 kb of
genomic DNA and contains 20 exons [3]. Its low mole-
cular weight standard isoform, CD44s, binds more
strongly to hyaluronate than high molecular weight
CD44 isoforms. The intracellular domain of CD44s
interacts with the cell cytoskeleton by binding directly
to ankyrin, and the interaction between ankyrin and
CD44s is required for the modulation of CD44s cell sur-
face expression and adhesion functions. CD44 has been
reported to play an important role in cancer cell inva-
sion and metastasis as well as in fundamental biological
processes, including lymphocyte homing, hematopoiesis,
inflammation, wound healing, and apoptosis [4,5].
The expression pattern of CD44 showed contradictory
results in various cancer types. CD44 expression is up-
regulated in several tumor types, such as breast cancer
[6], gastric cancer [7], bladder cancer [8], head and neck
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[4]. The down-regulation of CD44 has been reported in
other cancer types, including carcinoma arising from the
progression to dysplasia in Barrett’s esophageal epithe-
lium [11], metastatic endometrial cancer [12], high-
grade bladder transitional cell carcinoma [13], prostate
cancer [14], and high-grade brain tumors [15]. Consid-
erable variability exists in the clinical implications of
CD44s in various cancers. Some studies have demon-
strated that CD44 overexpression is related to more
aggressive disease [4,6-10], while others have shown that
loss of CD44 expression is associated with poor prog-
nosis [11-15]. Similar conflicts are observed in reports
regarding lung cancer [16-20]. The activation of CD44
isoforms also triggers resistance to chemotherapeutic
agents in non-small cell lung cancer (NSCLC) and colon
cancer cell lines [21,22].
Cyclooxygenase (COX) is the key enzyme in prosta-
glandin metabolism. COX-2 has been reported to be
highly expressed in various malignancies. COX-2
expression has been suggested to be correlated with
tumor aggressiveness and poor prognosis. Earlier studies
have observed individual roles for CD44 and COX in
embryogenesis, angiogenesis, cellular proliferation,
wound healing, as well as in pathophysiological condi-
tions, such as cancer and inflammation. COX-2 overex-
pression is known to be as a proximal mediator of
CD44-dependent invasion in NSCLC cells [23].
Thus, we investigated histogenic differences of the
immunostaining pattern of CD44s in surgical specimens
from NSCLC patients and their correlation with clinico-
pathological parameters and patient clinical outcomes.
We also investigated COX-2 expression to determine
any association with CD44s, clinicopathological para-
meters, and clinical outcome in these patients.
Methods
1. Patients and tissue specimens
All tissues investigated in the present study were
obtained from consecutive NSCLC patients. We exam-
ined two histological tumor subtypes, adenocarcinoma
(AC) and squamous cell carcinoma (SCC), to compare
the role of investigated markers based on histological
type. In total, 159 consecutive patients underwent cura-
tive (R0) resection (lobectomy or pneumonectomy)
between April 1997 and March 2003 at Seoul St. Mary’s
Hospital, which is affiliated with Catholic University of
Korea. The research was approved by the hospital’s
Institutional Review Board. Patient clinicopathological
data obtained from medical records included age, gen-
der, histopathological diagnosis, pathological tumor
stage, and the date of initial diagnosis, relapse, death, or
the last follow-up. Histological classification was per-
formed according to the World Health Organization
(WHO) criteria and post-operative pathological staging
was performed according to the American Joint Com-
mittee on Cancer (AJCC) staging criteria, 6
th edition.
2. Construction of the tissue microarray
All archival tissue samples were routinely fixed in for-
malin and embedded in paraffin wax. Representative tis-
sue areas were marked on standard hematoxylin and
eosin (HE) sections, punched out of the paraffin block
using a 2.0-mm punch, and inserted into a recipient
paraffin block. To decrease error introduced by sam-
pling and to minimize the impact of tissue loss during
processing, duplicate tissue cores per specimen were
arrayed on a recipient paraffin block. Sections (4 μm)
were cut from the completed array block and trans-
ferred to silanized glass slides.
3. Immunohistochemistry and analysis
Tissue sections were deparaffined by incubation in
xylene and rehydrated through graded ethanol-water
solutions. Endogenous peroxidase was blocked with 3%
H2O2 in methanol. Antigen retrieval was performed
with citrate buffer (pH 6.0) by heating in a microwave
vacuum histoprocessor (RHS-1; Milestone, Bergamo,
Italy) at a controlled final temperature of 121°C for 15
min, and then cooling to room temperature for 15 min.
The CD44s polyclonal antibody (R&D Systems, Minnea-
polis, MN) was diluted to 1:10 using a dilution buffer. The
COX-2 monoclonal antibody (Cayman, Ann Arbor, MI)
was diluted to 1:100. The primary antibodies were incu-
bated at room temperature for 1 h. Detection was per-
formed using a conventional labeled streptavidin/biotin
method (LSAB2 System-HRP; Dako). The color reaction
was incubated in 3,3’diaminobenzidine for 5 min and
hematoxylin counterstaining was used. CD44s and COX-2
immunostains were interpreted by a pathologist (C.K.J.)
who was blinded to the specific diagnosis and prognosis of
each case. For CD44s staining, staining intensities were
scored as no staining (0), weak staining (1+), moderate
staining (2+), or strong staining (3+). The percentage of
staining area was classified as follows: 0, 0%; 1, 1-10%; 2,
11-50%; 3, 51-100%. The intensity and percentage scores
were multiplied to yield a composite score of 1 to 9 for
each specimen. Composite scores of 1 3 were defined as
indicating low CD44s protein expression, and scores of 4
9 were considered to indicate high CD44s expression.
Additionally, for CD44s, only cell membranous staining
was considered to be positive. For COX-2 staining, tumors
were considered to demonstrate positive expression if ≥
10% of tumor cells were immunostained.
4. Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware (ver. 13.0; SPSS, Chicago, IL). Survival was
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event (recurrence or death) using the Kaplan-Meier
method. Following an intent-to-treat approach, non-can-
c e r - r e l a t e dd e a t h sa sw e l la sf o l l o w - u pl o s sw e r e
included in survival analyses, but were considered to be
censored data. Relationships among CD44s expression,
COX-2 expression, and clinicopathological features were
evaluated using Spearman’s rank coefficient or Fisher’s
exact probability test. The statistical significance of dif-
ferences in cumulative survival curves was evaluated
using the log-rank test. Multivariate survival analysis
was performed on all parameters that were found to be
significant in univariate analyses using the Cox propor-
tional hazards model by histological stratification. Survi-
val rates and odds ratios are presented with their 95%
confidence intervals (CIs). Statistical tests were two-
sided at the 5% level of significance.
Results
1. Patient clinical characteristics
In total, 159 paraffin blocks with tumor samples were
available from patients who had undergone surgery.
Regarding treatment, no patient received radiation or
chemotherapy preoperatively. The median follow-up
duration was 49.9 months (range, 0.6-148.3 months)
after the initial pathological diagnosis. Among the 159
patients, 64 (40.3%) died of their tumors and 95 (59.7%)
were still alive at the last follow-up. The overall 5-year
survival rate for resected NSCLC was 70.4%. The clinical
and pathological characteristics of the series are shown
in Table 1. The patients consisted of 123 males and 36
females, with a median age of 64 years (range, 19-88
years). Histologically, 82 patients (51.6%) had AC and 77
(48.4%) had SCC. Of those 159 patients, 26 (16.4%) had
well differentiated, 96 (60.4%) had moderately differen-
tiated, and 37 (23.3%) had poorly differentiated carci-
noma. In total, 77 (48.4%) patients received adjuvant
treatment. Patient characteristics were similar between
SCC and AC patients, but advanced age (P = 0.024) and
a male predominance (P <0 . 0 0 1 )w e r eo b s e r v e di nS C C
patients. Well-differentiated tumors were observed more
commonly in AC patients.
2. Immunohistochemical staining patterns
Of 159 consecutive patients, we were unable to analyze,
10 (6.3%, AC 5, SCC 5) of the punches for CD44s, due
to tissue loss during processing. Of 149 specimens,
CD44s-positive tumors, which were predominantly
observed in the membrane of the cancer cells (Figure
1A, B), were demonstrated in 107 (67.3%) and were
found more frequently with the SCC histological sub-
type (91.7%; P< 0.001) compared with the AC histologi-
cal subtype (Table 1). Of 159 specimens, COX-2 was
highly expressed in the cytoplasm of tumor cells (Figure
1C, D) with a positive rate of 75.5%. No significant dif-
ference in COX-2 expression was observed between AC
and SCC patients.
3. Correlation between expression of investigated factors
and clinicopathological features in AC and SCC cases
In Table 2, associations among CD44s expression, COX-
2 expression, and clinicopathological features in AC
cases are shown. High CD44s expression was signifi-
cantly correlated with more advanced regional lymph
node metastasis (P = 0.021). High COX-2 expression
Table 1 Clinical and pathologic characteristics of patients
(n = 159)
Characteristics AC SCC
No. of
patients
% No. of
patients
% p-value
No. of patients
included
82 77
Age (years), median
(range)
62.0 (19-82) 64.0(33-88)
< 60 35 42.7 22 28.6 0.024
≥ 60 47 57.3 55 71.4
Sex
Male 51 63.4 72 93.5 < 0.001
Female 31 37.8 5 6.5
Tumor size (n = 157)
< 3 cm 29 35.8 20 26.3 0.061
≥ 3 cm 52 64.2 56 73.7
T (n = 158)
1-2 72 87.8 61 80.3 0.076
3-4 10 12.8 15 19.7
Lymph node
metastasis
Negative 49 59.8 47 61.0 0.127
Positive 33 40.2 30 39.0
Stage
I 43 50.6 42 57.8 0.072
II 18 18.1 17 20.0
III 21 20.1 18 22.2
Tumor differentiation
Well 22 26.8 4 5.2 0.031
Moderately 41 50.0 55 71.4
Poorly 19 23.2 18 23.4
Adjuvant treatment
not done 45 54.9 37 45.1 0.241
done 37 45.1 40 51.9
CD44s (n = 149)
Low 36 46.8 6 8.3 < 0.001
High 41 53.2 66 91.7
COX-2 (n = 159)
Low 16 19.5 23 29.9 0.129
High 66 80.5 54 70.1
AC, adenocarcinoma; SCC, squamous cell carcinoma, COX, cyclooxygenase
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0.009), but was not significantly related to lymph node
metastasis. However, increased expression of CD44s and
COX-2 was not significantly related to any clinicopatho-
logical feature in SCC patients (Table 3). We also
explored the association between CD44s and COX-2
expression. However, no significant correlation was
found among the investigated markers in AC and SCC
patients (Table 4).
4. Overall survival with respect to clinicopathological
factors
For AC, univariate analysis of clinicopathological factors
relevant to patient survival revealed that the following
factors were statistically significant for the overall survi-
val of patients: regional lymph node metastasis status (P
<0.001), advanced tumor node metastasis (TNM) stage
(P< 0.001), lymphatic invasion status (P< 0.001),
advanced age (P = 0.027), and poor tumor differentia-
tion (P = 0.046). Additionally, high CD44s expression
demonstrated statistical significance for the overall sur-
vival of patients (P=0.016; data not shown). In multi-
variate analysis, significant predictors were lymph node
metastasis status (hazard ratio, 5.212; 95% CI, 2.222-
12.226; P < 0.001), high-grade tumor differentiation
(hazard ratio, 3.110; 95% CI, 1.020-9.484; P=0.046),
and high CD44s expression (hazard ratio, 3.152; 95% CI,
1.256-7.910; P=0.014; Table 5, Figure 2). For SCC, uni-
variate analysis of clinicopathological factors relevant to
patient survival revealed that the following factors were
statistically significant for the overall survival: more
advanced T stage (P< 0.001), advanced TNM stage (P
<0.001), regional lymph node metastasis status (P =
0.004), and lymphatic invasion status (P =0 . 0 3 9 ) .H o w -
ever, no association was observed with the investigated
markers (data not shown). In multivariate analysis for
Figure 1 Microscopic views of positively stained immunohistochemistry sections in non-small cell lung cancer. Immunoreactivity for
CD44s was detected predominantly in the membrane of tumor cells. Typical examples of CD44s immunopositivity in AC (×400; A) and SCC
(×400; B) histological subtypes. Immunoreactivity of COX-2 was detected predominantly in the cytoplasm of tumor cells. COX-2 immunopositivity
in AC (×400; C) and SCC (×400; D) histological subtypes.
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advanced T stage (hazard ratio, 2.537; 95% CI, 1.202-
5.355; P=0.015). Lymph node metastasis status was
marginally associated with survival (hazard ratio, 2.001;
95% CI, 0.954-4.197; P=0.066). No significant associa-
tion was observed between CD44s expression and clini-
cal outcome (P = 0.311; Table 5, Figure 2). We also
analyzed prognostic factors using multivariate analysis
for the overall population. Lymph node metastasis status
(hazard ratio, 3.553; 95% CI, 1.826-5.502; P < 0.001) and
advanced T stage (hazard ratio, 1.826; 95% CI, 0.996-
3.349; P = 0.052) were strong predictors for survival.
Discussion
The present study demonstrated that the staining pat-
terns of CD44s in NSCLC tissue varied according to his-
tological subtype. Additionally, high CD44s expression
was a negative prognostic marker with significance in
patients with resected NSCLC, particularly those with
AC histology, and was independent of tumor stage.
In the present study, the frequency of CD44s expres-
sion in all cases was 67.3% and this was observed more
frequently with SCC (91.7%) than in AC (53.2%) cases.
This tendency was observed in previous reports
[18,24,25]. A recent report also showed that high
expression of CD44v6, a CD44 isoform, was detected
more frequently in SCC than in other carcinoma types
[16]. Squamous cell carcinoma derives from dysplastic
or metaplastic stratified epithelia (i.e., from bland squa-
mous metaplasia to squamous cell carcinoma in situ,
and then finally to invasive carcinoma). In a recent
study by Leung et al., evaluating non-cancerous lung tis-
sue, membrane expression of CD44 was confined to the
surface of bronchial basal cells, alveolar macrophages,
and regenerating cuboidal pneumocytes of injured lung,
whereas no CD44 expression was observed in terminally
differentiated epithelial cells such as ciliated or non-
ciliated columnar cells of bronchial epithelium or type I
flat pneumocytes lining alveolar spaces [18]. In contrast,
squamous metaplasia showed strong CD44
Table 2 Clinicopathological factors and their relationship
to the expression of different proteins, assessed in AC
cases
Characteristics CD44s (n = 77) COX-2 (n = 82)
Low(%) High(%) Low(%) High(%)
Tumor differentiation
Well, 7(33.3) 14(66.7) 7(31.8) 15(68.2)
Moderately, poorly 29(51.8) 27(48.2) 9(15.0) 51(85.0)
p-value 0.117 0.085
Tumor size
< 3 cm 12(42.9) 16(57.1) 1(3.4) 28(96.6)
≥ 3 cm 24(50.0) 24(50.0) 14(26.9) 38(73.1)
p-value 0.547 0.009
Lymph node metastasis
N0-1 33(53.2) 29(46.8) 14(20.9) 539(79.1)
N2-3 3(20.0) 12(80.0) 2(13.3) 13(86.7)
p-value 0.021 0.397
Stage
I 20(48.8) 21(51.2) 10(23.3) 33(76.7)
II 8(53.3) 7(46.7) 3(16.7) 15(83.3)
III 8(38.1) 13(61.9) 3(14.3) 18(85.7)
p-value 0.616 0.373
Lymphatic invasion
Negative 19(42.2) 26(57.8) 11(23.4) 36(76.6)
Positive 16(53.3) 14(46.7) 5(15.2) 28(84.8)
p-value 0.345 0.364
AC, adenocarcinoma; COX, cyclooxygenase.
Table 3 Clinicopathological factors and their relationship
to the expression of different proteins, assessed in SCC
cases
Characteristics CD44s (n = 72) COX-2 (n = 77)
Low(%) High(%) Low(%) High(%)
Tumor differentiation
Well 0(0) 4(100) 1(25.0) 3(75.0)
Moderately, poorly 6(8.8) 62(91.2) 22(30.1) 51(69.9)
p-value 0.701 0.655
Tumor size
≤ 3 cm 1(5.6) 17(94.4) 6(30.0) 14(70.0)
> 3 cm 4(7.5) 497(92.5) 20(37.7) 33(62.3)
p-value 0.625 0.976
Lymph node metastasis
N0-1 5(8.1) 57(91.9) 21(31.3) 46(68.7)
N2-3 1(10.0) 9(90.0) 2(20.0) 8(80.0)
p-value 0.607 0.373
Stage
I 3(7.9) 35(92.1) 12(28.6) 30(71.4)
II 1(6.3) 15(93.8) 4(23.5) 13(76.5)
III 2(11.1) 16(88.9) 7(38.9) 11(61.1)
p-value 0.736 0.594
Lymphatic invasion
negative 5(13.2) 33(86.8) 11(27.5) 29(72.5)
positive 1(3.3) 29(96.7) 11(33.3) 22(66.7)
p-value 0.163 0.589
SCC, squamous cell carcinoma; COX, cyclooxygenase.
Table 4 Relationship between the expression patterns of
markers according to histological subtype
AC SCC
COX-2 COX-2
Low(%) High(%) Low(%) High(%)
CD44s Low(%) 9(25.0) 27(75.0) 1(16.7) 5(83.3)
High(%) 6(14.6) 35(85.4) 21(31.8) 451(68.2)
p-value 0.252 0.400
AC, adenocarcinoma; SCC, squamous cell carcinoma; COX, cyclooxygenase.
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in premalignant dysplasia, the entire thickness displayed
aberrant CD44 expression, indicating that squamous
malignant transformation is closely associated with
CD44 expression. Thus, squamous cell carcinoma essen-
tially recapitulates the staining pattern of normal bron-
chial basal cells. However, adenocarcinoma of the lung
is usually accompanied by a morphological decrease in
and subsequent loss of CD44 [16-18]. This discrepancy
may be related to the heterogeneous histogenetic origin
of adenocarcinoma of the lung. Additionally, the func-
tional role of CD44 has revealed different features of the
molecule in the two histological subtypes. In SCC, only
cells of the neoplastic stage can transduce subcellular
signals via CD44 [26], whereas CD44s down-regulation
in the NSCLC cell line H322, derived from a primary
bronchioalveolar carcinoma of the lung, may confer a
protective advantage by allowing escape from tumorici-
dal effector cells, including activated macrophages of the
host, thus promoting tumorigenesis [27].
The exact role of CD44s and its various isoforms in
tumorigenesis and tumor progression remains controver-
sial. For example, Liu et al. considered that the expression
of CD44s in gastric cancer tissue was much higher than
that in normal tissue and its high expression was asso-
ciated with tumorigenesis, metastasis, and the clinically
aggressive behavior of the adenocarcinoma [28]. However,
loss of CD44s expression has been found to correlate with
lymph node metastasis and unfavorable outcome in
patients with breast carcinomas [29]. The findings of the
present study, strong association between tumor tissue
expression of CD44s and advanced lymph node metastasis
in the AC histological subtype (P = 0.021), are also contro-
versial in the literature regarding NSCLC. According to
the report by Tran et al., concerning the analysis of forma-
lin-fixed, paraffin-embedded archival tissues from 49 SCC
and 49 AC cases, CD44s expression did not correlate with
tumor stage, recurrence, and survival rates, whereas
expression of the variant isoform, CD44v6, was particu-
larly associated with local lymph node metastasis in
Table 5 Multivariate analysis of clinicopathological characteristics and biological factors by overall survival rate
Characteristics Hazards ratio 95% CI P-value
Total cases
Lymph node metastasis (no/yes) 3.553 1.826-5.502 < 0.001
T stage (T1-2/T3-4) 1.826 0.996-3.349 0.052
AC
Lymph node metastasis (no/yes) 5.212 2.222-12.226 < 0.001
CD44s (low/high) 3.152 1.256-7.910 0.014
Tumor differentiation (well/moderately, poorly) 3.110 1.020-9.484 0.046
SCC
T stage (T1-2/T3-4) 2.537 1.202-5.355 0.015
Lymph node metastasis (no/yes) 2.001 0.954-4.197 0.066
CD44s (low/high) 0.311
CI, confidence interval; AC, adenocarcinoma; SCC, squamous cell carcinoma.
Figure 2 Overall survival of non-small cell lung cancer patients were stratified by CD44s expression according to histological subtype.
A) Overall survival for 82 adenocarcinoma patients. B) Overall survival for 77 squamous cell carcinoma patients.
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that increased CD44v6 expression was associated with
lymph node metastasis in NSCLC [19]. However, consid-
ering only NSCLC with AC histology, the level of CD44v6
expression had no significant association with lymph node
metastases or tumor stage in the study by Ramasami et al.
[20] Thus, it seems reasonable to predict that tumor inva-
sion and metastasis could be enhanced by the cell-ECM
interaction in CD44-overexpressed tissue or by cell-cell
interaction in CD44-deficient tissue.
Large-scale studies have shown that tumor stage is the
most consistent prognostic factor in patients with
NSCLC [30]. This fact accords with our current study in
which T and N stages (P < 0.001 and P =0 . 0 5 2 ,r e s p e c -
tively) were strong prognostic factors for overall survival.
We also explored the value of CD44s as a molecular
prognostic indicator according to NSCLC histology and
found that high CD44s expression predicted a poor
post-operative survival for curatively resected NSCLC
patients with AC histology (P = 0.014). For several other
cancers, while several studies have shown that overex-
pression of CD44s and its splice variants, particularly
CD44v6, are associated with poor prognosis and metas-
tasis [4,6-10], others have shown that downregulation of
CD44 expression correlated with adverse outcome
[11-15]. The exact role of CD44 in the biological beha-
vior and clinical prognosis of NSCLC also remains to be
defined. Hirata et al. reported that the 5-year survival
rate of patients with CD44v6-positive tumors was 50%,
which was significantly lower than that of CD44v6-nega-
tive patients (88%; P = 0.001), in 69 patients with stage I
NSCLC, 43 of whom had AC, and suggested that
CD44v6 expression could predict poor prognosis [31].
In contrast, recent reports have shown that patients
with tumors exhibiting low-level CD44 or CD44v6
expression had a worse post-operative survival than
those with high levels of CD44 in resected NSCLC
patients with AC or SCC histology [16,18]. Also, in
Tran et al.’s report, CD44s expression had no prognostic
role in the analysis of 49 SCC and 49 AC tissue speci-
mens [17]. These differing results in NSCLC may be
partially attributed to differences in antibodies used for
staining, different criteria for defining stain positivity,
and different patient demograp h i c ss u c ha sh i s t o l o g i c a l
subtype, tumor stage, adjuvant treatment, and insuffi-
cient SCC immunoreactivity. However, obviously, CD44
is a membrane-bound glycoprotein and mediates a com-
plex range of functions. Invasive and metastatic growth
can be mediated through the interaction of cell surface
CD44 with ECM components such as hyaluronan [32] or
cell-cell interactions [1]. CD44-hyaluronan aggregates are
essential for activation of metalloproteinase, which induces
tissue invasion and tumor growth factor-b [33]. Signaling
through CD44 in endothelial cells is also known to induce
COX-2 via vascular endothelial growth factor (VEGF) gen-
eration, proliferate endothelial cells, and increase neo-vas-
cularization [34]. CD44 expressed on the surface of cancer
cells has been shown to facilitate binding to endothelial P-
or L-selectin and increase tumor access to hematogenous
spread [35]. Additionally, CD44 acts as a co-receptor with
neighboring receptor tyrosine kinases, such as epidermal
growth factor receptor (EGFR) [36], hepatocyte growth fac-
tor receptor (c-MET) [37] and VEGF receptor (VEGFR)
[38], and induces the PI3K/AKT cascade and anti-apopto-
tic pathway [39], resulting in enhanced aggressiveness and
multi-drug resistance [40]. Recently, CD44 has also been
reported to be a possible cancer stem cell marker for
breast, pancreas, or colorectal cancer [41]. In bronchial
cells, CD44 is associated with stem cells, namely basal cells
and type 2 pneumocytes, and may act to anchor these cells
to the matrix and be important in migration during repair
or neoplasia. Furthermore, as mentioned above, CD44
expression is maintained throughout tumorigenesis in
squamous cell carcinoma and bronchioloalveolar carci-
noma, suggesting a histogenetic relationship between stem
cells and their respective tumors [18].
Although, in our study, the sample size was not suffi-
ciently large to make a final statement on the prognostic
value of CD44, it has clear clinical implications as a
therapeutic target. In phase I dose-escalation studies
with the humanized IgG1 monoclonal CD44v6 antibody
bivatuzumab, labeled with rhenium-186, the radiolabeled
antibody showed promising anti-tumor effects with con-
sistent stable disease at higher radioactive dose levels
and with only low toxicity in patients with refractory
head and neck SCC [42].
Conclusions
T h ep r e s e n ts t u d yh a ss h o w nt h a th i g hC D 4 4 se x p r e s -
sion may be strongly negatively associated with clinical
outcomes in patients with resected NSCLC, particularly
for those with AC histology. CD44s expression may be
useful in selecting the subgroup with benefit from adju-
vant chemotherapy. Although the present study demon-
strates clinical implications of CD44, the information
provided may suffer from some limitations, such as the
retrospective nature of the study, some patient selection
bias related to treatment at a single institution, and the
identification of a functional role of CD44 in NSCLC
that needs to be explored further in a larger cohort of
patients and in prospective studies.
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